Related references
Note: Only part of the references are listed.A molecular census of 26S proteasomes in intact neurons
Shoh Asano et al.
SCIENCE (2015)
Antibody- Drug Conjugates: An Emerging Concept in Cancer Therapy
Ravi V. J. Chari et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2014)
Systematic Comparison of Peptidic Proteasome Inhibitors Highlights the α-Ketoamide Electrophile as an Auspicious Reversible Lead Motif
Martin L. Stein et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2014)
A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors
Kyriakos P. Papadopoulos et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems
Oktay Tacar et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2013)
Dual-targeting delivery system for selective cancer cell death and imaging
Xizhe Tian et al.
CHEMICAL SCIENCE (2013)
Somatostatin receptor-mediated tumor-targeting drug delivery using octreotide-PEG-deoxycholic acid conjugate-modified N-deoxycholic acid-O, N-hydroxyethylation chitosan micelles
Meirong Huo et al.
BIOMATERIALS (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Somatostatin Receptors as Targets for Nuclear Medicine Imaging and Radionuclide Treatment
Helmut R. Maecke et al.
JOURNAL OF NUCLEAR MEDICINE (2011)
Somatostatin Receptor-Targeted Anti-Cancer Therapy
Li-Chun Sun et al.
CURRENT DRUG DELIVERY (2011)
DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs
Yves Pommier et al.
CHEMISTRY & BIOLOGY (2010)
Improvement of drug-like properties of peptides: the somatostatin paradigm
Oded Ovadia et al.
EXPERT OPINION ON DRUG DISCOVERY (2010)
90Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide
David L. Bushnell et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas.
Anas Younes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The persisting challenge of selective and specific proteasome inhibition
Michael Groll et al.
JOURNAL OF PEPTIDE SCIENCE (2009)
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome
Susan D. Demo et al.
CANCER RESEARCH (2007)
Opinion - Why is cancer drug discovery so difficult?
Alexander Kamb et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Radiolabeled carbohydrated somatostatin analogs: A review of the current status
HJ Wester et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2004)
Quantitating protein synthesis, degradation, and endogenous antigen processing
MF Princiotta et al.
IMMUNITY (2003)
Targeting delivery of paclitaxel into tumor cells via somatostatin receptor endocytosis
CM Huang et al.
CHEMISTRY & BIOLOGY (2000)
Share Paper
